CG Oncology (CGON) rose over 4% on Monday after the company said roughly 76% of patients in a phase 3 trial of cretostimogene for high-risk bladder cancer showed a complete response at some point.
As of Jan. 20, 46% of patients remained in complete response at 12 months, with 30 confirmed responses at 24 months.
The study evaluated cretostimogene monotherapy for high-risk Bacillus Calmette Guerin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ. Data show that 83 out of 110 patients in the trial achieved complete response at some point.
Data also showed that cretostimogene levels peaked immediately after administration and lasted locally for 4 to 5 days. There was no systemic exposure reported.
These results were presented at the recent annual European Association of Urology Congress in Madrid, Spain.
Price: 28.26, Change: +1.21, Percent Change: +4.47
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。